Image

Melanoma Research

Featured image for “Opdivo® (nivolumab) Approved as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma”
10/15/2023

Opdivo® (nivolumab) Approved as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma

October 13, 2023 17:30 ET| Source: Bristol Myers Squibb In the Phase 3 CheckMate -76K trial, Opdivo demonstrated a statistically significant…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
Featured image for “Notes from the Lab: Novel targets for immune checkpoint inhibitors”
09/17/2023

Notes from the Lab: Novel targets for immune checkpoint inhibitors

By Paul Bunk, Ph.D. candidate, Cold Springs Harbor Laboratory Survival rates of patients with melanoma have drastically improved in the…
Blog - Melanoma360
, 
Melanoma Research
Featured image for “Clinical Trials Catch Up”
08/15/2023

Clinical Trials Catch Up

Welcome to our new interview series called Clinical Trials Catch Up, an article delivered in a question-and-answer format designed to…
Blog - Melanoma360
, 
Melanoma Research
Featured image for “AIM’s Latest Newsletter: The Research Edition, July 2023”
08/01/2023

AIM’s Latest Newsletter: The Research Edition, July 2023

This month’s newsletter focuses on the latest news and scientific breakthroughs in melanoma research. This edition features: Letter from AIM’s…
Blog - Melanoma360
, 
Melanoma Research
Featured image for “Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma”
05/30/2023

Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma

May 26, 2023 17:30 ET| Source: Iovance Biotherapeutics, Inc. Priority Review Granted with Prescription Drug User Fee Act (PDUFA) Action Date…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
Featured image for “U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma”
02/28/2023

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma

February 28, 2023 | Source: PRINCETON, N.J.–(BUSINESS WIRE)–  The applications are based on results from the Phase 3 CheckMate -76K trial,…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
Featured image for “Notes from the Lab: T-Cell Engagers, the Next Stage in Cancer Immunotherapy?”
01/27/2023

Notes from the Lab: T-Cell Engagers, the Next Stage in Cancer Immunotherapy?

By Paul Bunk, Ph.D. candidate, Cold Springs Harbor Laboratory In January 2022, tebentafusp-tebn, also known under the more easily pronounceable…
Blog - Melanoma360
, 
Melanoma Research
Featured image for “A Letter From Our Vice President | January 2023”
01/26/2023

A Letter From Our Vice President | January 2023

  Happy new year to you and your families! I hope that 2023 has started well for you. Before I…
Blog - Melanoma360
, 
Melanoma Research
Featured image for “TISSUE IS THE ISSUE—2023 Update on AIM’s International Melanoma Tissue Bank Consortium”
01/26/2023

TISSUE IS THE ISSUE—2023 Update on AIM’s International Melanoma Tissue Bank Consortium

This article is an update of an article we published last year. AIM at Melanoma’s major research initiative—the International Melanoma…
Blog - Melanoma360
, 
Melanoma Research
Featured image for “What Makes AIM’s IMTBC Even More Valuable”
01/26/2023

What Makes AIM’s IMTBC Even More Valuable

AIM at Melanoma’s major research project, the International Melanoma Tissue Bank Consortium (IMTBC), is the first collaborative fresh frozen primary…
Blog - Melanoma360
, 
Melanoma Research
10/15/2023

Opdivo® (nivolumab) Approved as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma

October 13, 2023 17:30 ET| Source: Bristol Myers Squibb In the Phase 3 CheckMate -76K trial, Opdivo demonstrated a statistically significant…
Featured image for “Opdivo® (nivolumab) Approved as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
09/17/2023

Notes from the Lab: Novel targets for immune checkpoint inhibitors

By Paul Bunk, Ph.D. candidate, Cold Springs Harbor Laboratory Survival rates of patients with melanoma have drastically improved in the…
Featured image for “Notes from the Lab: Novel targets for immune checkpoint inhibitors”
Blog - Melanoma360
 | 
Melanoma Research
08/15/2023

Clinical Trials Catch Up

Welcome to our new interview series called Clinical Trials Catch Up, an article delivered in a question-and-answer format designed to…
Featured image for “Clinical Trials Catch Up”
Blog - Melanoma360
 | 
Melanoma Research
08/01/2023

AIM’s Latest Newsletter: The Research Edition, July 2023

This month’s newsletter focuses on the latest news and scientific breakthroughs in melanoma research. This edition features: Letter from AIM’s…
Featured image for “AIM’s Latest Newsletter: The Research Edition, July 2023”
Blog - Melanoma360
 | 
Melanoma Research
05/30/2023

Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma

May 26, 2023 17:30 ET| Source: Iovance Biotherapeutics, Inc. Priority Review Granted with Prescription Drug User Fee Act (PDUFA) Action Date…
Featured image for “Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
02/28/2023

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma

February 28, 2023 | Source: PRINCETON, N.J.–(BUSINESS WIRE)–  The applications are based on results from the Phase 3 CheckMate -76K trial,…
Featured image for “U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
01/27/2023

Notes from the Lab: T-Cell Engagers, the Next Stage in Cancer Immunotherapy?

By Paul Bunk, Ph.D. candidate, Cold Springs Harbor Laboratory In January 2022, tebentafusp-tebn, also known under the more easily pronounceable…
Featured image for “Notes from the Lab: T-Cell Engagers, the Next Stage in Cancer Immunotherapy?”
Blog - Melanoma360
 | 
Melanoma Research
01/26/2023

A Letter From Our Vice President | January 2023

  Happy new year to you and your families! I hope that 2023 has started well for you. Before I…
Featured image for “A Letter From Our Vice President | January 2023”
Blog - Melanoma360
 | 
Melanoma Research
01/26/2023

TISSUE IS THE ISSUE—2023 Update on AIM’s International Melanoma Tissue Bank Consortium

This article is an update of an article we published last year. AIM at Melanoma’s major research initiative—the International Melanoma…
Featured image for “TISSUE IS THE ISSUE—2023 Update on AIM’s International Melanoma Tissue Bank Consortium”
Blog - Melanoma360
 | 
Melanoma Research
01/26/2023

What Makes AIM’s IMTBC Even More Valuable

AIM at Melanoma’s major research project, the International Melanoma Tissue Bank Consortium (IMTBC), is the first collaborative fresh frozen primary…
Featured image for “What Makes AIM’s IMTBC Even More Valuable”
Blog - Melanoma360
 | 
Melanoma Research

Recent Posts

Featured image for “From a Scare to Awareness: Lindsay Willis’s Mission to Educate on Melanoma Risks”
Jul. 23, 2024

From a Scare to Awareness: Lindsay Willis’s Mission to Educate on Melanoma Risks

Featured image for “Everything Coming up Rosy is not a Health Tune”
Jul. 18, 2024

Everything Coming up Rosy is not a Health Tune

Featured image for “Ways to Give: How You Can Donate Your Birthday Through Facebook”
Jul. 10, 2024

Ways to Give: How You Can Donate Your Birthday Through Facebook

Featured image for “Beyond the Clinic Podcast: Navigating the Storm: Managing Stress and Anxiety Through Your Cancer Journey”
Jul. 10, 2024

Beyond the Clinic Podcast: Navigating the Storm: Managing Stress and Anxiety Through Your Cancer Journey

Featured image for “Summary of Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma”
Jul. 02, 2024

Summary of Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma

Filter by Tag